Antibody Ingredients TRIZ Cases

Selective framework humanization reduces immunogenicity while CDR retention maintains high binding affinity for PD1 signaling.

Piperazine linkers stabilize antibody-eribulin conjugates, resolving thiosuccinimide instability and reducing systemic toxicity.

Engineered humanized anti-SIRPα antibodies resolve binding specificity contradictions by targeting SIRPα variants while avoiding SIRPγ cross-reactivity.

Anti-IL18BP antibodies neutralize inhibitory binding proteins to restore IL-18 signaling, overcoming clinical efficacy limits caused by receptor blockade.

Antibodies inhibit CTLA-4 activity to enhance T cell activation while preserving immune checkpoint control for cancer treatment.

Humanized anti-SFRP2 antibodies reduce metastatic tumor growth and lower serum protein levels while sparing normal cells from damage.

Anti-presenilin antibodies reduce NOTCH expression to treat cancer while avoiding blood-brain barrier penetration.

An anti-NG2 antibody triggers caspase-dependent apoptosis in cancer cells through autonomous signal transduction.

Antibodies with modified amino acid sequences in variable regions improve IL4Rα blocking activity to inhibit signal transduction.

Targeting the delta1 chain extracts harmful gamma delta T cells from the tumor microenvironment, overcoming limited response rates in existing cancer therapies.

Asparagine-to-glutamine mutations in STEAP-1 binding antibodies resist succinimide degradation while preserving T cell activation efficacy.

Antibodies bind Programmed Death-1 to induce ligand-like signaling, resolving competition with PD-L1 while modulating T cell activity.

Anti-CKAP4 monoclonal antibodies inhibit DKK1 binding by targeting precise epitope regions, resolving low specificity issues in prior polyclonal approaches.

Antibody-mediated extraction of cocaine from circulation reduces brain concentrations while increasing plasma levels, resolving the distribution trade-off.

A bispecific antibody physically links CD22 to the CD79 receptor to inhibit B cell activation.

Antibodies targeting the ADAM15 metalloprotease domain inhibit angiogenesis by blocking protease activity.

Reducing core fucose to under 10% boosts ADCC activity fifty-fold over Rituximab while suppressing CDC activity.

An anti-HVEM monoclonal antibody binds human HVEM with high affinity to inhibit BTLA interactions.

High affinity human 4-1BB binding proteins enhance antitumor immune responses by modulating receptor activities and synergizing with checkpoint inhibitors.

Antibodies targeting TREM1 repolarize suppressive myeloid cells, converting harmful T-cell suppression into enhanced anti-tumor immunity.

Dual targeting of CD33 and CD7 antigens via bispecific antibody drug conjugates overcomes off-target toxicity and relapse in acute myeloid leukemia treatment.

Monoclonal antibody binds GRP78 epitopes on cancer cell surfaces to enable targeted internalization.

Imipramine overcomes chemotherapy resistance in triple-negative breast cancer by disrupting DNA repair mechanisms and enhancing immunotherapy efficacy.

Sequential antibody administration depletes regulatory T cells then stimulates immune responses to enhance cancer treatment efficacy.

Targeting GM-CSF and IL-5 via CD131-binding antibodies reduces inflammatory infiltration while avoiding adverse side effects of broad immunosuppressants.

Laser capture microdissection isolates specific cells from tissue sections to select antibodies binding internalizing epitopes.

Non-peptide linkers expand chemical space in antibody-drug conjugates while maintaining lysosomal cleavage.

Modified polypeptides extend serum half-life to maintain stable IL-6 inhibition, reducing dosing frequency and symptom fluctuations.

Anti-C3d antibodies target deposited C3d to overcome antigen loss from trogocytosis and enable preclinical animal models.

A bispecific antibody binds EGFR and c-Met receptors to inhibit tumor growth in liver cancer.

Anti-CEACAM5 immunoconjugates bind tumor antigens to deliver cytotoxic payloads, reducing off-target toxicity while maintaining response rates.

Combining CDR-based PD-L1 binding with CH3 domain LAG-3 targeting blocks dual immune suppression pathways.

Merges neoantigen vaccines with PD-1, PD-L1, and TIGIT inhibitors to reverse T cell exhaustion and reduce tumor volume in pancreatic cancer.

Monoclonal antibodies bind human CD112R to prevent Nectin-2 interaction and restore T cell activity.

Engineered Fc variants modify specific amino acid residues to enhance binding affinity for activating human Fc gamma receptors.

An asymmetric bispecific antibody format combines scFv and Fab domains to achieve targeted immune cell activation while preventing bivalent binding toxicity.

Merges antibody and vaccine therapies to resolve the trade-off between enhanced antitumor activity and increased treatment complexity.

Classify antibodies by reactivity using flow cytometry to identify specific antigens and reduce time required for antibody identification.

Measuring p38 MAPK activation distinguishes agonistic from antagonistic anti-B7-H1 antibodies to prevent T cell survival compromise.

Optimized humanized antibodies resolve binding affinity and cytotoxicity contradictions, enabling potent cancer cell lysis via enhanced ADCC activity.

Antibodies targeting CCR7 receptors selectively eliminate tumor cells, preventing metastasis while sparing healthy tissue.

CyCAT segmented antibodies resolve T-cell activation specificity versus side effects by requiring dual antigen presence.

Recombinant anti-CD133 monoclonal antibodies bind conserved extracellular peptide sequences to detect both glycosylated and unglycosylated CD133 variants.

Combining anti-KIR antibody 1-7F9 with lenalidomide enhances natural killer cell cytotoxicity against tumor cells.

CCR5 binding agents maintain sustained receptor occupancy through engineered half-life extension.

Modifying CDR amino acid sequences reduces cytokine release while maintaining target cell killing efficacy in cancer therapies.

A multivalent antibody complex binds the human protein CD99 to induce cell death in leukaemia cells.

Acidic pH-selective antibodies bind VISTA in tumors, reducing off-target effects and enhancing immune response.

Periodic crizanlizumab dosing blocks P-selectin adhesion, reducing annual pain crisis rates by 30-70% while improving patient adherence compared to hydroxyurea.